Gebe Kadınlarda Toxoplasma, Rubella ve Sitomegalovirüs Serum Antikorlarının Sıklığı

Amaç: Gebelik esnasında geçirilen enfeksiyonlar anne ve fetüs açısından morbidite ve mortalite nedenlerinden biridir. TORCH konjenital enfeksiyonlara neden olan mikroorganizmalardır. TORCH enfeksiyonunun önlenmesi ve tedavisi, anne ve çocuk sağlığı için çok önemlidir. Bu çalışmada gebe kadınlar arasında bu enfeksiyonların seroprevalansını belirlemeyi amaçladık. Gereç ve Yöntemler: Toplam 1371 gebe kadının laboratuvar verileri retrospektif olarak değerlendirildi. Toxoplasma, Rubella ve Cytomegalovirus IgM ve IgG antikorları, Carbonylmetalloimmunoassay metodu ile test edildi. Bulgular: Laboratuvar verileri incelenen gebe kadınların yaşları 17 ile 47 arasında değişmekte olup, yaş ortalaması 30,1 ± 5,2 idi. Toxoplasma IgG antikoru %36,3 pozitif bulunurken, %1 oranında ise Toxoplasma IgM antikoru pozitifti bulundu. Rubella IgG seropozitifliği %94,3 iken Rubella IgM % 0,7 oranında saptandı. CMV IgG ve IgM pozitiflikleri sırasıyla %94,1 ve %0,9 olarak tespit edildi. Sonuç: Antenatal risk gruplarının saptanması konjenital sendromların önlenmesinde önemli bir adımdır. Bu yüzden öncelikle o bölgeye ait seropozitiflik oranlarının bilinmesi çok önemlidir. Yaygın popülasyon taraması, TORCH ajanları nedeniyle konjenital enfeksiyonların önlenmesine katkıda bulunabilir. Prevalans yüksek olmadığı için Toxoplasma gondii taraması önerilebilir. Yüksek seroprevalans nedeniyle CMV taraması anlamlı değildir. Anti-rubella IgG seropozitifliğinin yüksek olması bu bölgedeki gebelerin bağışıklık düzeyinin yüksek olduğunu göstermektedir.

Prevalence of Serum Antibodies to Toxoplasma, Rubella, Cytomegalovirus among Pregnant Women

Aim: Infections during pregnancy are one of the causes of morbidity and mortality for mother and fetus. TORCH arethe microorganisms that cause congenital infections. Prevention and treatment of TORCH infection is very importantfor maternal and child health. In this study, we aimed to determine the seroprevalence of these infections amongpregnant women.Material and Methods: Laboratory data of 1371 pregnant women were evaluated retrospectively. Toxoplasma,Rubella and Cytomegalovirus IgM and IgG antibodies were tested by the carbonylmetalloimmunoassay method.Results: The ages of pregnant women whose laboratory data were examined, varied between 17 and 47, and the meanage was 30.1 ± 5.2. Positive Toxoplasma IgG antibody was found 36.3%, while 1.0% were positive for the ToxoplasmaIgM antibody. Rubella IgG seropositivity was found 94.3%, and Rubella IgM was found 0.7%. CMV IgG and IgMpositivities were detected in 94.1% and 0.9% respectively.Conclusion: Detection of antenatal risk groups is an important step in the prevention of congenital syndromes.Therefore, it is very important to know the seropositivity rates of that region. The common population screening maycontribute to the prevention of congenital infections due to TORCH agents. Toxoplasma gondii screening can berecommended because the prevalence is not high. CMV screening is not significant due to high seroprevalence. Highanti-rubella IgG seropositivity shows that pregnant women in this region have high immunity levels.

PDF

___

1. Natalie N, Duchon J, Zachariah P. TORCH infections. Clin Perinatol. 2015; 42(1): 77-103.
2. Leeper C, Lutzkanin A. Infections during pregnancy. Prim Care. 2018; 45(3): 567-86.
3. Li Z, Yan C, Liu P, Yan R, Feng Z. The prevalence of the serum anti-bodies to TORCH among women before pregnancy or in the early period of pregnancy in Beijing. Clinica Chimica Acta. 2009; 403(1-2): 212-5.
4. Padmavathy M, Gowri M, Malini J, Umapathy BL, Navaneeth BV, Bhatia M, et al. Seroprevalence of TORCH infections and adverse reproductive outcome in current pregnancy with bad obstetric history. J Clin Biomed Sci. 2013; 3(2): 62-71.
5. Stegmann BJ, Carey JC. TORCH Infections. Toxoplasmosis, other (Syphilis, Varicella-zoster, Parvovirus B19), rubella, cytomegalovirus (CMV), and herpes infections. Curr Womens Health Rep. 2002; 2(4): 253-8.
6. Akpınar O, Akpınar H, Şendil KE. Seroprevalence of toxoplasma gondii among pregnant women in Isparta province, Turkey. Düzce Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi. 2017; 7(3): 133-6.
7. Numa O, Vural F, Aka N, Alpay M, Coşkun ADE. TORCH seroprevalence among patients attending obstetric care clinic of Haydarpaşa training and research hospital affiliated to association of İstanbul northern Anatolia public hospitals. North Clin Istanb. 2015; 2(3): 203-9.
8. Karabulut A, Polat Y, Türk M, Işık Balcı Y. Evaluation of rubella, toxoplasma gondii, and cytomegalovirus seroprevalences among pregnant women in Denizli province. Turk J Med Sci. 2011; 41(1): 159-64.
9. Altunal LN, Esen AB, Karagöz G, Yaşar K. Seroprevalence of toxoplasma gondii, rubella, and cytomegalovirus among pregnant refugees and Turkish women: a retrospective comparative study. SCIE. 2018; 29(4): 235-9.
10. Ocak S, Zeteroğlu S, Özer C, Dolapçıoğlu K, Güngören A. Seroprevalence of toxoplasma gondii, rubella and cytomegalovirus among pregnant women in southern Turkey. Scand J Infect Dis. 2007; 39(3): 231-4.
11. Tamer GS, Dundar D, Caliskan E. Seroprevalence of toxoplasma gondii, rubella and cytomegalovirus among pregnant women in western region of Turkey. Clin Invest Med. 2009; 32(1): 43-7.
12. Wysokinska T, Janaszek W, Bucholc B, Gorska P, Gniadek G, Slusarczyk J, et al. The prevalence of anti-rubella antibodies in women of childbearing age in Poland. Vaccine. 2004; 22(16): 1899-2.
13. Armstrong N, O’Donnell N. Anniversary of rubella epidemic. Lancet. 2004; 364(9431): 32.
14. Pandolfi E, Gesualdo F, Rizzo C, Bella A, Agricola E, Mastroiacovo P, et al. Global seroprevalence of rubella among pregnant and childbearing age women: a meta-analysis. Eur J Public Health. 2017; 27(3): 530-7.
15.Çetinkaya RA, Yenilmez E. The seroprevalence of Rubella in pregnant women in Turkey: a metaanalysis research of 90988 Rubella IgM, 84398 Rubella IgG, and 522 avidity results. Turk J Obstet Gynecol. 2019; 16(1): 63-71.
16. Sert UY, Özgü Erdinç, AS, Saygan S, Engin ÜY. The Prevalence of anti-rubella antibodies in pregnant women of Turkey, results of 94508 patients in a tertiary referral center. Z Geburtshilfe Neonatol. 2019; 223(5): 281-4.
17. Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C. Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta‐ analysis. Rev Med Virol. 2019; 29(3): 1-6.
18. Akpınar O, Akpınar H. Investigation of the rubella and cytomegalovırus seroprevalences by ELISA method ın pregnant women. Balıkesir Health Sci Jour. 2017; 6(1): 11-5.
19. Dwyer DE, Cunningham AL. Herpes simplex and varicellazoster virus infections. Med J Aust. 2002; 177(5): 267-73.
20. Stephenson FA, Gardella C. Herpes simplex virus infection during pregnancy. Obstet Gynecol Clin North Am. 2014; 41(4): 601-14.
21. Şimşek M, Keşli R, Demir C, Çetinkaya Ö, Arıöz DT. Investigation seroprevalence of toxoplasma, rubella, cytomegalovirus and herpes simplex virus type 2 in pregnant women followed in the Application and Research Hospital. Afyon Kocatepe University. Ortadogu Medical Journal. 2016; 8(1): 1-6.